The expression of PD-L1 was upregulated after CAR-T-cell infusion, and the use of an anti-PD-L1 antibody may effectively restore the function of CAR-T cells and endogenous T cells recruited to the tumor site (NCT02414269) [139]. The gene discussed is CD274; the disease is neoplasm.